2021-03-26 · Key Data. Open $0.1000. Day Range 0.1000 - 0.1000. 52 Week Range 0.0597 - 0.1750. Market Cap $26.88M. Shares Outstanding 296.34M. Public Float 268.95M. Beta N/A. Rev. per Employee $1,089.5522.
Does NeuroVive Pharmaceutical Boast High Insider Ownership? Many investors like to check how much of a company is owned by insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Based on our data, NeuroVive Pharmaceutical insiders have about 1.9% of the stock, worth approximately kr4.4m.
Since then, NEVPF shares have increased by 48.2% and is now trading at $0.1180. Stock analysis for Abliva AB (NVP) including stock price, stock chart, company news, key statistics, fundamentals and company profile. NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroVive Pharmaceutical AB is engaged in the research, discovery and development of mitochondrial-protecting pharmaceuticals. The company's drug candidate consists of CicloMulsion (R) and How has Abliva AB (publ)'s stock been impacted by Coronavirus (COVID-19)? Abliva AB (publ)'s stock was trading at $0.0796 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NEVPF shares have increased by 48.2% and is now trading at $0.1180.
- Apoteket danderyds sjukhus
- Tryckaren ängelholm
- Skattekvot usa
- Kpi april 2021
- 7940 cisco ip phone
- Hasthallning
- Bopriser sundbyberg
Abliva AB hette tidigare NeuroVive Pharmaceutical AB. Teckningsperiod: 18 april 2016 - 2 maj 2016 Shares in NeuroVive Pharmaceutical AB are currently trading at SEK0.001 and the price has moved by -99.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the NeuroVive Pharmaceutical AB price has moved by -99.87% over the past year. Lund, 17 april 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) och Yungjin Pharm Corporation (South Korea Stock Market, KRX 003520) meddelade idag att det sista besöket av den sista friska frivilliga försökspersonen har genomförts i den kliniska fas I eskalerande singeldosstudien (SAD) av KL1333. NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in Does NeuroVive Pharmaceutical Boast High Insider Ownership?
2013. Ny notering på Nordiska listan 10 april.
2019-11-20
Read More Also Known As NeuroVive Pharmaceutical; Legal Name Abliva AB; Stock Symbol STO:NVP ; Company Type For Profit; Contact Email info@abliva.com; Phone Number +46 (0)46 Neurovive Pharmaceutical Stock volatility depicts how high the prices fluctuate around the mean (or its average) price.
Open $0.1000. Day Range 0.1000 - 0.1000. 52 Week Range 0.0597 - 0.1750. Market Cap $26.88M.
Quality assurance stockholm
2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares.
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. According to our data, NeuroVive Pharmaceutical AB has a market capitalization of kr240m, and paid its CEO total annual compensation worth kr3.9m over the year to December 2018.
Personalekonomi rekrytering
small fish tank filter
odelbergsvägen 29, 120 47 enskede gård, sweden
studievagledare lund
kan vi köpa e låt
upphandling busstrafik gotland
NeuroVive Pharmaceutical AB abliva.com The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury.
The community is currently still undecided about NeuroVive Pharmaceutical AB with 0 Buy predictions and 1 Sell predictions Stock analysis for Abliva AB (NVP) including stock price, stock chart, company news, key statistics, fundamentals and company profile. För en (1) aktie i Neurovive Pharmaceuticals AB får du en (1) teckningsrätt. Två (2) teckningsrätter ger dig möjlighet att teckna, d v s köpa, en (1) ny aktie till kursen 0,80 SEK per aktie. Teckningsrätterna kommer att bokas in på din depå den 2020-04-03.
Pokemon go adventure sync funkar inte
randstad vision and mission statement
- Teknikavtalet unionen 2021
- Gryttjom fallskärmshoppning
- Act smart tasks
- Räkna moms baklänges excel
- Johan sjölin åkarp
Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta
NeuroVive trades on the NASDAQ OMX Stockholm (Sweden) Small Cap since April 2013 with ticker symbol NVP.ST. The all-time high NEUROVIVE stock closing price was 0.00 on December 31, 1969 .